Released : March 03, 2021 07:00 RNS Number : 9363Q MaxCyte, Inc. 03 March 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Gaithersburg, Maryland - 3 March 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces
Released : February 23, 2021 07:00 RNS Number : 9618P MaxCyte, Inc. 22 February 2021 FOR IMMEDIATE RELEASE MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences GAITHERSBURG, MD , February 23, 2021 - MaxCyte, Inc., a global cell-based
Released : February 19, 2021 07:00 RNS Number : 6562P MaxCyte, Inc. 19 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Total Voting Rights Gaithersburg, Maryland - 19 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global
Released : February 17, 2021 17:44 RNS Number : 4895P MaxCyte, Inc. 17 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, Maryland - 17 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global clinical-stage cell-based therapies and life sciences
Released : February 15, 2021 16:32 RNS Number : 1618P MaxCyte, Inc. 15 February 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : February 12, 2021 13:59 RNS Number : 9907O MaxCyte, Inc. 12 February 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : February 08, 2021 14:59 RNS Number : 3605O MaxCyte, Inc. 08 February 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
Released : February 05, 2021 09:01 RNS Number : 1447O MaxCyte, Inc. 05 February 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review
Released : February 04, 2021 07:00 RNS Number : 9342N MaxCyte, Inc. 04 February 2021 GENERAL TEXT AMENDMENT The following amendment(s) have been made to the ' MaxCyte Announces £40 million Subscription' announcement released on 03/02/2021 at 16.36 under RNS No 9191N. References to "T.
Released : February 04, 2021 07:00 RNS Number : 9374N MaxCyte, Inc. 04 February 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings and Issue of Equity Gaithersburg, Maryland - 4 February 2021: MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences
